A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Clinical trial NCT06891066 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06891066
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-14
- Primary completion
- 2027-08-10
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.